Bioprocessing solutions for vaccines

The development of vaccines has primarily targeted infectious diseases, but new developments are now focusing on immuno-oncology applications. The production of influenza vaccines is moving away from the use of fertilised eggs to bioprocessing applications employing primary cells or cell lines.

Maintaining the integrity and activity of the vaccine during upstream production to downstream purification and through final fill can be successfully achieved with products from VWR, part of Avantor.

VWR, part of Avantor supplies a broad range of raw materials and ancillary materials for early discovery phase through product development, pre-clinical, scale-up, and commercial manufacturing. Choose from a range of animal sera products used to enhance attachment and growth of adherent cells, cell culture media and transfection reagents, excipients used in drug product formulation, and single-use product assemblies to enable aseptic fluid transfer throughout the process.

Vaccine manufacturing: COVID-19 and beyond

In this interview, Nandu Deorkar, Vice President of R&D, Biopharma Production at Avantor, shares lessons we can learn from the industry’s historic ramp-up from research to manufacturing.

Read more

  • Contact us

Avantor J.T.Baker® brand offers the only cGMP manufactured IPTG to ICHQ7 standards, providing biopharma researchers and manufacturers with a solution to help scale novel vaccines from research and development to clinical then full scale manufacturing with speed, quality and confidence.

Vaccines workflow

Ready to get started?

Our Bioprocessing Solutions team can help!

Yes, let's get started!